Kura Oncology (NASDAQ:KURA) Upgraded at Lifesci Capital

Kura Oncology (NASDAQ:KURA) was upgraded by investment analysts at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. JMP Securities restated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Finally, Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $29.20.

Kura Oncology Trading Down 2.0 %

NASDAQ:KURA opened at $17.02 on Tuesday. The company has a market cap of $1.30 billion, a P/E ratio of -7.84 and a beta of 0.84. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The business has a 50 day moving average price of $19.41 and a two-hundred day moving average price of $20.13. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the firm posted ($0.53) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. As a group, analysts expect that Kura Oncology will post -2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. nVerses Capital LLC bought a new stake in shares of Kura Oncology during the 3rd quarter worth about $25,000. Quarry LP acquired a new stake in Kura Oncology during the second quarter worth approximately $196,000. Alethea Capital Management LLC boosted its holdings in shares of Kura Oncology by 2.4% during the second quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after acquiring an additional 6,300 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after purchasing an additional 1,976 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after purchasing an additional 58,422 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.